Summary: Experience using low-dose radioiodine given six-monthly instead of yearly in hyperthyroid patients with Graves' disease is reported. One hundred and thirtyfive patients have been treated over a three-year period with 74 MBq (2 mCi) doses of 131I. IThirty-eight Ipercent were controlled with a single dose. Those patients requiring more than one dose were treated with a further 74 MBq (2 mCi) "'lI at six-monthly intervals until euthyroid. Using this approach, 46% were euthyroid one year after starting treatment, and 75% were euthyroid at two years. The incidence of hypothyroidism following treatment was 2.2% at one year, with a yearly incidence thereafter of 4-6%.
Introduction
The use of radioiodine is well established as a safe and effective treatment for hyperthyroidism (Halnan 1983) . Whilst several large series have analysed the number of euthyroid and hypothyroid patients after radioiodine treatment, there is little published data on the time taken for patients to become euthyroid with this method of treatment. The use of low-dose regimens reduces the incidence of hypothyroidism following treatment (Goolden & Russell Fraser 1969 , Smith & Wilson 1967 ) but many patients require more than one dose of radioiodine to become euthyroid. Conventionally, repeated doses of radioiodine are given, when necessary, at yearly intervals. This results in a considerable delay in achieving control, particularly for the 20-30% of patients who require three or more doses when low-dose regimens are used.
Between 1972 and 1978, hyperthyroid patients with Graves' disease were treated at this hospital using 2 mCi'3'I, repeated yearly as required (Lowdell et al. 1985) . From January 1979 the treatment policy in the Royal Marsden Hospital Thyroid Clinic was modified so that patients remaining hyperthyroid after their first dose of 131I were given repeated doses as necessary every six months until euthyroid. Patients requiring fl-blockers for control of symptoms remain on these throughout.
Patients are then seen at six weeks after administration of radioiodine and subsequently every 2-3 months. Where appropriate, antithyroid medication is gradually withdrawn. Thyroid function tests (T4, T3 and TSH) are repeated prior to each visit so that results of recent tests are available when patients are seen in the clinic. Patients remaining hyperthyroid after six months are given a further dose of 74 MBq (2 mCi) 13'I. Patients are designated euthyroid when they remain clinically and biochemically euthyroid, having discontinued all antithyroid medication.
Results
Between January 1979 and December 1981, 140 patients were selected for initial treatment with 74 MBq (2 mCi) 131. Five died within a few months of treatment with radioiodine without documentation of their thyroid status, the causes of death being alcoholic cirrhosis (1), carcinoma of the breast (1), ischaemic heart disease (2), and pneumonia and renal failure (1). This report concerns the remaining 135 patients.
Eighteen patients who remained thyrotoxic after initial treatment with 74 MBq (2 mCi) 1311 subsequently received 370 MBq (10 mCi) doses. This was on the basis of a multinodular goitre on thyroid scanning after their initial therapy dose of radioiodine. All other patients received repeated doses of 74 MBq (2 mCi) 1 311, as described above.
Patients have been followed up for a mean period of 3.6 years. Only 9 patients remain thyrotoxic (2 have had two doses 131I, 3 have had three doses, and 4 have had five doses). In addition, 3 patients became directly hypothyroid after their final dose of 13'I. The general characteristics of the population are shown in Table 1 .
Fifty-one patients (38%) required only a single dose of radioiodine. The only striking difference between this group and those requiring more than one dose was the low female:male ratio. Of the 135 patients, 13 (54%) of the 24 males compared with 38 (34%) of the 111 females required only a single dose. The relationship between age, time from diagnosis, previous treatment and antibody status is shown in Table 2 . There appears to be no relationship between these parameters and number of doses of radioiodine required. Previous medical treatment in these patients was carbimazole for varying lengths of time with relapse on withdrawal, and in 3 cases propylthiouracil was used because of intolerance to carbimazole. Surgery in all cases had been partial thyroidectomy. Twelve of the 16 patients treated surgically also had medical treatment prior to referral. Thirty (22%) patients had had no previous treatment, being referred for 131I as their primary treatment. The high proportion of patients requiring three doses having had previous surgery, and of those requiring four doses having had previous medical treatment, is probably related to the small numbers of patients in these groups. The principal aim of this study was to assess the time taken to achieve control. As expected, the time from first referral to the Thyroid Clinic to becoming euthyroid increased with the number of doses required (Table 3) . It is of interest that the time taken to become euthyroid following the final dose of radioiodine was remarkably constant. It can be seen from Figure 1 that 46% of patients were euthyroid after one year and 75% after two years. The characteristics of the 22 patients who became hypothyroid are compared with those of the total patient population in Table 4, and Tables 5 and 6 show the time taken to become hypothyroid and its relation to the number of doses of radioiodine given. The one-year incidence of hypothyroidism appeared to be very low and after that a yearly incidence of 4-6% was seen. There is no relationship between number of doses given and incidence of hypothyroidism. Of the 10 patients who developed hypothyroidism within six months of their final dose of '3'I, 2 had received a single dose, 3 had received two doses, 4 had received three doses and one had received four doses.
Discussion
The use of radioiodine in Graves' disease has been advocated as the treatment of choice for the majority of adults (Becker 1984) , having definite advantages over the alternatives of surgery or antithyroid medication. The adoption of low-dose 131j has reduced the incidence of hypothyroidism following this procedure. However, this continues to be a problem, with a cumulative incidence in the present series of 4-6% per year, and one recent large series reported an incidence after one year of 12%, with a cumulative incidence of 76% at 11 years (Srimada et al. 1984 ). This cumulative effect is explained by radiation damage to DNA causing progressive loss of cells as they are stimulated to divide (Al-Himadi & Wilson 1965) . However, the natural history of untreated Graves' disease shows a variable incidence of hypothyroidism and this should also be considered in interpreting the results of any treatment (Irvine et al. 1977) .
The main disadvantage of low-dose treatment lies in the delay in patients becoming euthyroid, with around half of all patients requiring a second dose of radioiodine and up to a third requiring three or more doses. In this study it was hoped that by giving subsequent doses where required at six-monthly rather than yearly intervals, the delay in achieving normal thyroid function might be reduced. The patients in this study were comparable with those reported elsewhere in terms of age, sex ratio, antibody status and previous treatment, and after treatment a similar incidence of hypothyroidism was seen. The difference of note seen in this study was the preponderance of males requiring only a single dose of radioiodine for control.
The incidence of hypothyroidism in the first year appears particularly low and some workers have suggested that pretreatment with antithyroid drugs may reduce the incidence of early hypothyroidism (Aro et al. 1981 , Connell et al. 1984 . One of the 3 patients who became hypothyroid in the first year had had no previous treatment; the other 2 had received carbimazole for six and seven months respectively. Over the four years there was no evidence that previous treatment influenced the incidence of hypothyroidism.
In this study 46% of patients had become euthyroid at one year from initial treatment with radioiodine, rising to 75% at two years. These periods are perhaps slightly longer than might theoretically be expected from six-monthly scheduling of radioiodine, but this may be explained by the fact that some patients require more than six months tojhave their carbimazole tailed off when seen every 2-3 months in the clinic. Because of this, whilst most patients who require subsequent doses of radioiodine do so within six months, some will have longer periods between doses, being controlled on a small reducing dose of carbimazole but relapsing some time after stopping medication completely.
The finding that there appears to be a consistent period of 4-5 months (mean 4.7 months) after the final dose of 1311 for a patient to become euthyroid is of some interest, and suggests that six-monthly intervals between doses is optimum and any further reduction is inappropriate, increasing the risk of treating patients who have already had sufficient 131I to become euthyroid.
An alternative approach in treating Graves' disease with radioiodine is to give a large ablative dose with the intention of inducing hypothyroidism, which is then treated with appropriate thyroxine replacement. One recent study found that after a single dose of 555 MBq (15 mCi), 64% of patients became hypothyroid within the first year and a further 27% became euthyroid (Kendall-Taylor et al. 1984) . Thus, most patients can have their hyperthyroidism controlled within the first year by this approach -but the price of this is lifelong thyroxine replacement. In the present study, in which frequent small doses of radioiodine were used, 46% of patients were euthyroid at one year (and only 2.2% hypothyroid), and at two years 75% were euthyroid with 8% hypothyroid. It is clearly preferable to restore patients to the euthyroid state if at all possible, so that the majority of patients need no further medication.
The incidence of hypothyroidism in these patients is at present 4-6% per year, in keeping with other low-dose series, but clearly this needs to be interpreted with caution since a continuing incidence of hypothyroidism is to be expected and careful follow up of these patients with regular thyroid function tests remains essential.
In conclusion, therefore, this approach retains the advantages of low-dose radioiodine whilst overcoming the major disadvantage -that is, the time taken to achieve control. Longer follow up will reveal whether the present low incidence of hypothyroidism persists. There is probably no ideal dose schedule for radioiodine, since rapid control of hyperthyroidism and low incidence of hypothyroidism are mutually exclusive. There are clear indications for high-dose 131I treatment (Hamberger & Sukhannery 1968) : where there are cardiac symptoms (Scott et al. 1984 ), a multinodular goitre or a single toxic nodule. In Graves' disease without cardiac complications, where radioiodine is now considered the treatment of choice, sixmonthly low-dose 1311 may provide more rapid control than other low-dose regimens, with a lower incidence of hypothyroidism than with larger doses of radioiodine.
